



MacroGenics, Inc.
Investor Relations Department
9640 MEDICAL CENTER DRIVE
Rockville, MD 20850
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: MGNX

Last Trade:	19.19
Trade Time:	4:00 PM ET Jan 19, 2018
Change:	0.30 (+1.588%)
Day Range	18.53 - 19.40
52-Week Range	14.36 - 22.31
Volume	259,937

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceu... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jan 18, 2018

[Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium](#)

Jan 4, 2018

[MacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

Jan 4, 2018

[MacroGenics Enters Research Collaboration with Roche to Develop a Novel Bispecific Molecule](#)

Dec 11, 2017

[Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting](#)

Dec 5, 2017

[MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Feb 28, 2017

[Annual Report \(10-K\)](#)

Apr 4, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 8, 2017

[Quarterly Report \(10-Q\)](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)